[Pneumonia after cytostatic drug therapy].
On account of its high mortality, pneumonia is a particularly feared infectious complication in granulocytopenic patients. One of the main reasons for the fatal outcome is the increasing rate of pulmonary mycoses. Fungal infections offer considerable problems concerning diagnostics and therapy. To improve the prognosis of pulmonary mycoses undelayed diagnostics--even by more invasive methods like bronchoalveolar lavage--and immediate start of antifungal treatment (Amphotericin B/5-Flucytosine are still considered as standard therapy) is necessary. A further problem are gram positive organisms, insufficiently prevented by the standard prophylactic regimens. Particularly pneumonia by Staphylococcus aureus and Viridans-Streptococci may show lethal outcome. The initial treatment with glycopeptides is discussed. Treatment of infections by gram negative organisms however, is less controversial. Finally pneumonias in granulocytopenic patients present serious problems in diagnostics and therapy requiring interdisciplinary co-operation of hematology, radiology, pneumology and microbiology.
Böhme
A
A
Abt. Hämatologie/Onkologie, J. W. v. Goethe-Universität Frankfurt am Main.
Hoelzer
D
D
D000380:Agranulocytosis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000139:chemically induced*; D011014:Pneumonia / Q000139:chemically induced*
D000970:Antineoplastic Agents
Pneumonien nach Zytostatikatherapie.